TABLE 1.
Participant clinical parameters
| Supplementation | |||
| Parameters | Basal (week 0) | OM-3a (2 g) (week 8) | Follow-up (week 16) |
| Age (years) | |||
| Male | 31.3 ± 2.5 | — | — |
| Female | 38.0 ± 1.8 | — | — |
| Body weight (kg) | |||
| Male | 79.9 ± 5.6 | 80.8 ± 6.1 | 81.2 ± 6.2 |
| Female | 68.4 ± 4.6 | 68.2 ± 4.6 | 68.0 ± 4.6 |
| BMI (kg/m2) | |||
| Male | 24.9 ± 1.0 | 24.9 ± 1.0 | 24.9 ± 1.0 |
| Female | 25.5 ± 1.3 | 25.5 ± 1.3 | 25.5 ± 1.3 |
| Heart rate (bpm) | 64.4 ± 2.1 | 67.4 ± 2.1 | 67.9 ± 2.1 |
| Systolic blood pressure (mmHg) | 123.2 ± 2.9 | 121.3 ± 2.9 | 121.2 ± 2.9 |
| Diastolic blood pressure (mmHg) | 75.5 ± 1.7 | 72.0 ± 1.7 | 73.4 ± 1.7 |
| Total cholesterol (mmol/l) | 5.2 ± 0.2 | 5.6 ± 0.2 | 5.2 ± 0.2 |
| LDL (mmol/l) | 3.1 ± 0.2 | 3.4 ± 0.2 | 3.2 ± 0.2 |
| HDL (mmol/l) | 1.4 ± 0.1 | 1.5 ± 0.1 | 1.4 ± 0.1 |
| Triglycerides (mmol/l) | 1.5 ± 0.2 | 1.1 ± 0.2 | 1.2 ± 0.2 |
All values are expressed as mean ± SEM.
a
OM-3, EPA/DHA-supplement as described in Materials and Methods.